AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...